Chugai Pharmaceutical announced that Roche will discontinue clinical development of the anti-myostatin antibody emugrobart for spinal muscular atrophy and facioscapulohumeral muscular dystrophy. Development targeting obesity will continue.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4519","jir_company_name":"Chugai Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-03-23","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/03\/4519-20260323-01.pdf","jir_short_summary":"Chugai Pharmaceutical announced that Roche will discontinue clinical development of the anti-myostatin antibody emugrobart for spinal muscular atrophy and facioscapulohumeral muscular dystrophy. Development targeting obesity will continue.","jir_summary":"### Overview of Development Discontinuation\nChugai Pharmaceutical has decided to discontinue clinical development of the anti-latent myostatin sweeping antibody emugrobart (GYM329), developed by Roche, for spinal muscular atrophy (SMA) and facioscapulohumeral muscular dystrophy (FSHD). This decision is based on data evaluations from the Phase II\/III MANATEE trial (SMA) and the Phase II MANOEUVRE trial (FSHD), which did not demonstrate consistent or robust muscle mass increase or motor function improvement, and thus lacked sufficient evidence to proceed to Phase III trials. There were no safety issues observed and tolerability was favorable.\n\n### Future Outlook and Impact\nClinical trials of emugrobart targeting obesity will continue based on scientific rationale, so this development discontinuation does not affect the obesity indication. There is no impact on the consolidated earnings guidance for the fiscal year ending December 2026. Since obesity differs from neuromuscular diseases and involves a different mechanism of action for the anti-myostatin antibody, the Phase II trial will proceed as planned.","jir_financial_highlights":"Diseases Subject to Development Discontinuation: Spinal Muscular Atrophy (SMA), Facioscapulohumeral Muscular Dystrophy (FSHD) (Development discontinuation decided)\nClinical Trial Phase: Phase II\/III (SMA), Phase II (FSHD) (Discontinued)\nDevelopment Targeting Obesity: Ongoing (No impact)","jir_category":"","jir_hashtags":"#ChugaiPharmaceuticalCoLtd, #DrugDevelopmentDiscontinuation, #PharmaceuticalDevelopment, #JapaneseStocks","jir_key_figures":"Diseases Subject to Development Discontinuation: Spinal Muscular Atrophy (SMA), Facioscapulohumeral Muscular Dystrophy (FSHD)\nClinical Trial Phase: Phase II\/III (SMA), Phase II (FSHD)\nClinical Trials Targeting Obesity: Planned to continue","jir_meta_title":"Chugai Pharmaceutical Announces Discontinuation of GYM329 Development for SMA and FSHD; Obesity Development Continues","jir_meta_description":"Chugai Pharmaceutical has discontinued development of Roche's anti-myostatin antibody emugrobart for spinal muscular atrophy and facioscapulohumeral muscular dystrophy. Development for obesity continues with no impact on fiscal 2026 earnings guidance.","jir_og_title":"Chugai Pharmaceutical Announces Discontinuation of GYM329 Development for SMA and FSHD","jir_og_description":"Chugai Pharmaceutical announces discontinuation of development for certain indications of the anti-myostatin antibody emugrobart. Development for obesity indication continues with no impact on earnings.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":6836,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"product_announcement","footnotes":""},"sector":[],"importance":[],"class_list":["post-35638","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n